CLS003 / Maruho  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CLS003 / Maruho
NCT02333643 / 2014-003688-39: A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.

Completed
2
81
Europe
CLS003, Furosemide, Digoxin, Vehicle topical
Maruho Co., Ltd.
Cutaneous Warts
08/15
08/15
2018-000034-36: Topical ionic contra-viral therapy in actinic keratosis

Ongoing
2
32
Europe
Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel
Cutanea Life Sciences, Cutanea Life Sciences
Actinic keratosis, Actinic keratosis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2016-000870-39: Digoxin / Furosemide topical therapy for genital warts and VIN lesions of immunocompromised and immunocompetent patients

Not yet recruiting
2
48
Europe
Ionic Contra-Viral Therapy (ICVT) comprised of digoxin and furosemide, CLS003, Gel
Cutanea Life Sciences, Cutanea Life Science
HPV-induced genital lesions of immunocompromised and immunocompetent patients, Genital warts or Vulval HSIL, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT03334240: ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Terminated
2
28
Europe
CLS003, Vehicle
Maruho Co., Ltd.
HPV-Induced Genital Lesions
10/18
10/18
NCT02106260 / 2013-005569-38: First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts

Completed
1/2
12
Europe
CLS003
Maruho Co., Ltd.
Cutaneous Warts
04/14
 

Download Options